SCHEMBL2218183

SCHEMBL2218183

CSc1c(C(=O)NNC(=O)C(C)(C)C)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1

nearest known ligand 0.67

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 11/20 0.67
CNR1 P21554 6/20 0.67
PPARA Q07869 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4460349 0.87 CNR2 (0.77) CNR2CNR1PPARA
SCHEMBL2219238 0.85 CNR2 (0.74) CNR2CNR1
SCHEMBL2984070 0.82 CNR2 (0.69) CNR2CNR1
SCHEMBL2973902 0.81 CNR2 (0.68) CNR2CNR1
SCHEMBL2977322 0.80 CNR1 (1.00) CNR2CNR1
Lithium Ion SCHEMBL2973901 0.80 CNR2 (0.67) CNR2CNR1
SCHEMBL2980193 0.80 CNR1 (1.00) CNR2CNR1
SCHEMBL2987455 0.80 CNR1 (1.00) CNR2CNR1
SCHEMBL31478247 0.78 CNR2 (0.83) CNR2CNR1PPARA
SCHEMBL4462996 0.78 CNR2 (0.83) CNR2CNR1PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309584-B2 Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists GREEN CROSS CORPORATION (KR) 2012-11-13 US disclosed
US-20110178140-A1 SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS GREEN CROSS CORPORATION (KR) 2011-07-21 US disclosed
WO-2010035915-A1 SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS GREEN CROSS CORPORATION (KR) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178140-A1 SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS CNR1, CNR2, GPR119 CNR2 2/4885CNR1 1/4885PPARA 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.